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Abstract
The prognosis of early breast cancer (BC) relies on cell autonomous and immune parameters. The impact of the intestinal
microbiome on clinical outcome has not yet been evaluated. Shotgun metagenomics was used to determine the composition of the
fecal microbiota in 121 specimens from 76 early BC patients, 45 of whom were paired before and after chemotherapy. These
patients were enrolled in the CANTO prospective study designed to record the side effects associated with the clinical
management of BC. We analyzed associations between baseline or post-chemotherapy fecal microbiota and plasma metabolomics
with BC prognosis, as well as with therapy-induced side effects. We examined the clinical relevance of these findings in
immunocompetent mice colonized with BC patient microbiota that were subsequently challenged with histo-compatible mouse
BC and chemotherapy. We conclude that specific gut commensals that are overabundant in BC patients compared with healthy
individuals negatively impact BC prognosis, are modulated by chemotherapy, and may influence weight gain and neurological
side effects of BC therapies. These findings obtained in adjuvant and neoadjuvant settings warrant prospective validation.
Introduction
Breast cancer (BC) ranks first in women, and is the second
cause of death in this gender. In addition to ageing and
genetics, environmental factors (diet, ethanol consumption,
endocrine disruptors, sedentary lifestyle) may contribute to
the development of the disease. Several mechanisms might
account for the putative impact of the microbiota on BC
incidence or severity. Triple negative breast cancer
(TNBC), whose cells do not express estrogen and proges-
terone hormone receptors and failed to express Her2 in
in situ hybridization and immunohistochemistry, are kept in
check by the immune system, as indicated by the predictive
impact of tumor infiltrating lymphocytes on the efficacy of
chemotherapy and prognosis [1–3] and the clinical benefit
mediated by immune checkpoint inhibitors in PDL-1
expressing TNBC [4]. Accumulating evidence points to
the capacity of the intestinal ecosystem, and more specifi-
cally specific health-associated bacteria commensals to
dampen systemic inflammation [5, 6], to shape the innate
and adaptive immune tonus [7–10], and reprogram the
tumor microenvironment in tumor bearing mice [11, 12]
and patients treated with immunotherapy [13, 14]. Retro-
spective and prospective studies conducted in lung, kidney,
and melanoma cancers highlighted that antibiotics (ATB)
negatively impact cancer patients’ clinical outcome during
therapy with anti-PD1, or anti-PDL-1 antibodies [15–18]. In
parallel, metagenomics analyses scrutinizing the repertoire
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of intestinal commensalism indicated that the alpha and/or
beta diversity as well as the precise taxonomic composition
of the microflora dictate the prognosis of patients with
melanoma [12, 14], kidney [19], and lung [11] cancer.
However, no data are currently available on the impact of
the gut microbiota in shaping cancer immune surveillance in
the context of TNBC.
Of note, on theoretical grounds, hormone receptor positive
(HR+) BC may sense the gut microbiome in a different way
than TNBC. Pioneering findings implicated that long-term
estrogen supplementation (which is usually applicated for
alleviation of menopausal symptoms) impacted composition of
gut microbiota and microbial activity, and affected estrogen
metabolism in the gut of mice [20]. The diversity and com-
position of the gut microbiota may increase BC risk by mod-
ulating systemic levels of estrogens and inflammation [21].
Pioneering reports also underscored the positive effects
mediated by dietary interventions on BC incidence or prog-
nosis [22]. Nicotinamide that can be produced by microbial
components of the gut could reduce breast tumorigenesis in a
T and NK cell-dependent manner [23]. In mice and patients
with HR+ BC, periodic fasting or a fasting-mimicking diet
enhanced the activity of the endocrine therapeutics by low-
ering circulating insulin, insulin-like growth factor-1, and
leptin and by inhibiting trophic signaling by the AKT–mTOR
pathway [24]. Soy isoflavone influenced the composition of
the gut microbiota and tumor aggressiveness in immunode-
ficient mice humanized by fecal transfer of BC stools and
inoculated with human BC implants [25].
Thus far, very few studies investigated the taxonomic
diversity of commensals in women diagnosed with early BC.
Hence, time is ripe to study the microbiota repertoire, its
modulation by adjuvant treatments and its relevance for the
outcome and side effects of therapies. Here we unveil for two
independent cohorts of early BC that specific metagenomics
species influence BC prognosis and neurological, endocrine
and digestive side effects of chemo-hormono-therapy, open-
ing new avenues for the future clinical management of BC.
Results
Fecal microbiota composition at diagnosis is
associated with prognosis of early BC
We determined the metagenomics (MG)-based composition
of stools at diagnosis of early BC in a subgroup (N= 76) of
a deep cohort called “CANTO” (for CANcer TOxicities,
NCT01993498). The CANTO study aims at performing a
long-term follow-up of 13 250 women treated for BC over a
period of ten years in order to quantify and prevent chronic
toxicities related to treatment (surgery, radiation therapy,
chemo-hormono-therapy) (refer to Consort diagram,
Supplementary Fig. S1). The present analysis focuses on a
first set of 9595 pts Enrolled from 2012–2017 with suffi-
cient follow-up and mature data in 2019. Among the 76
females that signed the informed consent to get MG stool
analysis, the median age was 52 (Supplementary Table S1).
About 43% patients presented with a T2-T3 tumor size, and
51% with a Scarff Bloom& Richardson Grade 3 (Gr 3)
adenocarcinoma (Supplementary Table S1). Up to 42 and
34% of tumors expressed HR or HER2, respectively, (24%
were TNBC) and 46% presented with lymph node invol-
vement (at least 1 N+) (Table S1). Overall, 14% presented
with AJCC stage III. The adjuvant (or neoadjuvant) therapy
consisted in anthracycline-taxane (93%), taxane- (7%)
based chemotherapy (CT) and/or hormonotherapy (62%)
(Supplementary Table S1).
The composition of the gut microbiota ecosystem was
evaluated using shot gun metagenomics (MG) profiling of
early BC patients pre- (N= 76) and post-chemotherapy
(CT) (N= 45), the post-chemotherapy specimen being
paired with the pre-CT ones. To address whether the
microbial composition differed between patients presenting
with a favorable (T1, Gr 1, N-, AJCC stage 1) versus
unfavorable BC prognosis (T2-3, Gr 3, N+, AJCC stage II/
III), we performed univariate analysis of the variations in
fecal microbial α diversity and provided principal coordi-
nate analyses (PCoA) of microbial β-diversity distances
within these patient subsets. Alpha diversity (observed OTU
or Shannon index) did not significantly vary among these
groups (not shown). Exploratory analysis of β-diversity
(measuring sample diversity) was calculated using the
Bray–Curtis measure of dissimilarity. As we observed that
the fecal microbiota β-diversity discriminated groups of
patients according to tumor size (< or >pT1, Supplementary
Fig. S2A, C), to Scarff Bloom& Richardson grade (Gr1/2
versus Gr3, Supplementary Fig. S3A, B), to axillary node
involvement (N- versus N+, Supplementary Fig. S4A, C)
and to TNM staging (stage I versus stage II–III, Fig. 1A, D),
we utilized a supervised analysis (Partial Least Squares
Discriminant Analysis (PLS-DA) to explore the variance
between the groups at baseline and post-CT (Fig. 1, Sup-
plementary Figs. S2, S3, S4). To determine the relative
contribution of the relative abundance of each bacterial
species (spp) to the observed group separation at baseline
and post-CT, bacterial spp were ordered according to their
variable importance plot (VIP) score which relies on the
supervised analysis of PLS-DA, comparing groups of
patients according to each BC prognosis factor (< or >pT1
in Supplementary Fig. S2B, D, Gr1/2 versus Gr3 in Sup-
plementary Fig. S3C, N- versus N+ in Supplementary
Fig. S4B, D, and stage I versus stage II/III in Fig. 1B, E).
Several consortia of commensals were found iteratively
overrepresented in patient subsets bearing more aggressive
tumors (associated with larger tumors at diagnosis, axillary
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Fig. 1 Metagenomics-based stool composition is associated with
TNM staging in early breast cancer (BC) patients. A and D. Beta-
diversity ordination plot based on principal coordinate analysis of
normalized and standardized data of fecal microbiota composition
before (A; pre-CT, A, n= 56) and after (D; post-CT, D, n= 34)
adjuvant chemotherapy in patients with stage I (orange) and stage II-III
(blue). The p-value is indicated at the top of the Y axis. B and E.
Variable importance plot (VIP) scores were obtained within partial
least square discriminant analysis by segregating stage I (orange) from
stage II-III (blue), describing the most discriminant species in des-
cending order of importance before (B; pre-CT-A, n= 56) and after E;
post-CT, D, n= 34) adjuvant chemotherapy (only bacteria with pre-
valence >2.5% were taking into account). C and F. Differential
abundances in terms of metabolic pathways between study groups
(stage I vs stage II-III, pre- CT (C) vs post-CT (F)) by computing the
effect size from linear discriminant analysis (LDA).
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node involvement (N+), and UICC staging ≥II) in fecal
specimen harvested pre- and/or post-CT, such as species
belonging to the Streptococcus genera (S. mitis, S. vesti-
bularis), Lachnospiraceae family members (Sellimonas
intestinalis, Eisenbergiella massiliensis, Blautia wexlerae),
Veillonella genus (V. atypica, V. parvula), Bacteroides spp
(P. merdae, B. uniformis, B.xylanisolvens…), E. ramosum,
Enterobacteriaceae family members such as Bilophila
wadsworthia, Hafnia alvei and Klesiella spp, Clostridiaceae
family members (C. spiroforme, C. asparagiforme, C.
boltae) that we previously reported in advanced NSCLC
and kidney cancer patients manifesting a primary resistance
to immune checkpoint inhibitors [11, 19] (Fig. 1, Supple-
mentary Figs. S2B, D and S4B, D). Conversely, health-
associated commensals, i.e., Methanobrevibacter smithii
archae, Eubacteriaceae family members (such as E. eligens,
E. hallii, E. rectale), A. muciniphila, Defulfovibrio piger,
species belonging to the Coprococcus genus (C. comes, C.
catus) and Collinsella genus (C. aerofaciens), B. vulgatus
as well as Ruminococcaceae family members (R. bicircu-
lans, R. lactaris) were reproducibly associated with N- or
≤pT1 BC in longitudinal samples (Fig. 1, Supplementary
Figs. S2, S3, S4B–D). Of note, A. muciniphila, C. aero-
faciens, and distinct Bacteroides spp. have already been
linked to favorable outcome in advanced melanoma,
NSCLC and kidney cancer patients responding to immune
checkpoint inhibitors [10–12, 19]. The functional pathways
associated with these bacterial patterns were different
between good and bad prognosis BC, but similar pre-and
post-CT (Fig. 1C, F). Increased biosynthesis of L-Arginine
and adenosine ribonucleotides, dominance of oxoglutarate
ferredoxin oxidoreduction, and adenine–adenosine salvage
were observed in favorable BC, while biosynthesis of lipids,
thiamine diphosphate, pyridoxal −5 phosphate, L-threonine
and degradation of L -histidine were associated with poor-
prognosis cancers (Fig. 1C, F).
Next, to further analyze the clinical relevance of these
commensals associated with favorable or unfavorable
prognosis, we scrutinized fecal compositional differences
between these 76 BC and 54 Italian healthy volunteers
(HV), whose feces were harvested according to the same
procedures and analyzed together with 282 HV-derived
samples selected from referenced public metagenomes. Of
note, these 282 HV were randomly permutated several
times and analyzed for data validation (as detailed in
M&M). Species with differential abundance between cancer
free (HV) and BC groups were used as input for the linear
discriminant analysis (LDA) to calculate an effect size
(LEfSe method, LDA score > 2) (Fig. 2A). We found bac-
terial commonalities between N- groups and cancer free
individuals (Fig. 2B) and between N+ and BC status
(Fig. 2C). Hence, we identified 7 MG species associated
with both a cancer -free status and with a more favorable
prognosis, in case of cancer (mostly N- and/or TNM staging
I) in post-CT specimen, such as C. comes and C. catus,
Collinsella aerofaciens, E. rectale, M. smithii, or MG
recovered in both pre- and post- CT feces (such as B.
crossotus, C. aerofaciens) (Fig. 2B). Conversely, we iden-
tified 7 commensals characterizing BC patients and asso-
ciated with worse prognosis in pre- or post-CT specimens
such as B. uniformis and C. bolteae (N+ and TNM staging
>I), P. merdae, C. asparagiforme, R. intestinalis, B. intes-
tinihominis (Fig. 2C).
Next, we attempted to validate these findings in a second
independent cohort of BC patients treated with neo-
adjuvant CT enrolled in CANTO (n= 17 pre-CT, 10
post-CT) (Supplementary Table S1). Here again, the LEfSe
method allowed to segregate baseline stool compositions of
BC patients with post-chemotherapy pN+ versus pN- status
(Fig. 2D) as well as pathological complete responders (stage
0) from non-complete responders (stage I–II) (Supplemen-
tary Fig. S3D). B. vulgatus, Blautia obeum and Dorea
formicigenerans that were found overrepresented post-CT
in stage I BC (Fig. 1E, Fig. 2A) stood out among the few
taxons associated with the pN- status (metastasis-free axil-
lary lymph nodes post-neoadjuvant CT) (Fig. 2D). In con-
trast, 8 MG species described in N+ or stage II-III post-CT
(i.e., E. ramosum, C. bolteae, C. citroniae, C. aldenense,
C. clostridioforme, Blautia wexlerae, Sellimonas intestina-
lis, Eisenberghiella massiliensis) and overabundant in BC
patients as compared to HV (Fig. 2A) were also sig-
nificantly associated with the pN+ status in post-
neoadjuvant CT specimen, but not with cancer immuno-
histochemical subtype (Fig. 2D, Supplementary Fig. S3D).
Altogether, using four complementary methodologies of
comparisons, sampling pre-CT, sampling post-CT, cancer
-free versus cancer bearing status, and adjuvant versus
neoadjuvant settings, we conclude that the intestinal eco-
system represents another variable to consider in women at
early BC diagnosis, that possibly influences prognosis (as
based on correlations with tumor size, histological grade,
axillary LN involvement and staging). Of note, in this
cohort of 76 early BC, MG stool composition was asso-
ciated with the presence of axillary metastases in univariate
analyses identically to the classical clinical prognostic
parameters (Supplementary Table S2).
Adjuvant chemotherapy modified the β diversity of
fecal composition in early BC
To characterize changes (if any) in microbial composition
over the course of 8 cycles of CT, we first analyzed the
variations in fecal microbial α diversity (Fig. 3A) and per-
formed PCoA of microbial β diversity distances (Fig. 3B).
Compared with baseline (prior to CT), α diversity (richness
index) increased after CT (Fig. 3A, p= 0.033). When
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Fig. 2 Metagenomics analyses of stool samples from BC patients
compared with healthy volunteers (HV). A LEfSe (Linear dis-
criminant analysis of effect size) method was used to detect differential
abundant species (only bacteria with a prevalence >2.5% were con-
sidered) between (green bars, n= 336) and BC patients (BC, red bars,
n= 76). Venn diagram describing the listing and the numbers of
bacterial species in common between no pathological lymph node
involvement (pN−) and HV (n= 7, B) and in common between
pathological lymph node involvement (N+) and BC (n= 7, C). D.
VIP scores by comparing species abundance according to the patho-
logical lymph node involvement (no pathological lymph node invol-
vement, pN-, orange; pathological lymph node involvement, pN+,
blue) in stools collected after neoadjuvant CT (n= 10).
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considering β diversity variations in a paired manner, we
identified significant shifts in the microbial composition over
time (Fig. 3B, p= 0.032). Chemotherapy increased the
relative abundance of health-related MG species (such as
Methanobrevibacter smithii archae associated with HV and
pN- status in BC (Fig. 2B),D. formicigenerans (overabundant
Fig. 3 Chemotherapy significantly affected fecal composition in a
paired sub-group analysis. A. Alpha diversity in terms of richness in
longitudinal and paired stool samples (n= 45) collected before (pre-
CT, green) and after (post-CT, red) CT. B. Beta-diversity ordination
plot based on principal coordinate analysis of normalized and stan-
dardized data of fecal microbiota composition in pre-CT (green) and
post-CT (red) stools. Most discriminative species (C; through VIP
(implemented within partial least square discriminant analysis) and
pathways (D; through LEfSe) by differentiating between pre-CT and
post-CT samples stools. lasma levels of metabolites through high
dimensional metabolomics according to pathological lymph node
involvement (no pathological lymph node involvement, pN-; patho-
logical lymph node involvement, pN+) in terms of Glutamine (in pN-
patients, n= 18, left panels; and pN+ patients, n= 16, right panels). E
Ornithine (in pN- patients, n= 18, left panels; and pN+ patients, n=
16, right panels) F and Kynurenine to Tryptophan (Kyn/Trp) ratio in
pN- patients monitored in patients pre-CT, (green) and post-CT, (red),
n= 18 (G). P values are indicated at the top of the Y axis
(Wilcoxon test).
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in HV, Fig. 2A), R. torques (associated with stage I BC,
Fig. 1B, E pre-et post-CT, Fig. 3C). In contrast, CT tended to
reduce the over-representation of bacteria associated with BC
diagnosis and unfavorable prognosis (such as C. aspar-
agiforme, B. uniformis, Eggerthella lenta, species from the
Veillonella genus) (Fig. 3C). Of note, chemotherapy did not
significantly affect the relative abundance and prevalence of
the immunogenic species A. muciniphila, associated with
≤pT1, in pre-CT stool samples (not shown). Interestingly, the
functional pathways associated with bacterial gene patterns
were influenced by CT, which increased L-ornithine bio-
synthesis, glycolytic intermediates (glucose-6-phosphate and
fructose-6-phosphate), L-glutamate degradation, lipid bio-
synthesis, and ketogenesis (Fig. 3D).
To validate these metabolic patterns associated with fecal
content, we performed a metabolomic analysis of the
plasma in 29 BC females (26 pre- and 29 post-CT samples)
compared with age matched HV. Indeed, we confirmed that
glutamine and L-ornithine plasma levels increased during
CT, mostly in pN- (Fig. 3E, F). Conversely, the trypto-
phane/kynurenine degradation pathway, known to be
involved in lymphocyte exhaustion and associated with
advanced staging in BC stools (Supplementary Fig. S5A)
was stimulated by CT, mostly in pN- (Fig. 3G).
L -methionine (increased in stool gene patterns within
patients >T1) tended to increase in the plasma of stage II-III
patients post-CT (Supplementary Fig. S5B, C, right and left
panel respectively). Krebs cycle metabolites were higher in
stools of pN+ versus pN- and increased in plasma post- CT
in pN+ (Fig. S5B). The iNOS regulator dimethylarginine
was increased in the plasma post CT at later stages of BC,
while L-arginine biosynthesis was found in stools of good
prognosis BC (Supplementary Fig. S5D).
Altogether, significant changes occurred in the stool
composition after 8 cycles of adjuvant anthracyclines and
taxanes, expanding commensals associated with more
favorable prognosis, the metabolic pathway of polyamines
(L-Arg, L ornithine) and glutamine synthesis.
Gut microbiota and chemotherapy-related side
effects in CANTO
The LEfSe method was used to compare the abundance of
all bacterial clades pre- and post-CT according to the
occurrence of toxicity at 12 months, considering neurolo-
gical, gastrointestinal, rheumatological, or metabolic (BMI)
disorders (Supplementary Table S3). The α-diversity of the
gut microflora was not significantly different between
patients with or without side effects pre-CT, but varied post-
CT according to BMI, diarrhea and constipation (Supple-
mentary Figs. S6A, C and S7B, D). In univariate analysis,
β-diversity post-CT significantly predicted neurological side
effects (comprising paresthesia, peripheral sensory
neuropathy, memory disorders, concentration defects)
(Fig. 4A, p= 0.013, Supplementary Table S3), as well as
overt weight gain (Supplementary Fig. S6), constipation,
diarrhea or hot flashes, while rheumatological side effects
were not significantly associated with the gut composition
(Supplementary Fig. S7). 51 patients had neurological side
effects at month 12 while 16 did not. Bacterial taxa with
differential abundance between study groups complaining
or not from neurological side effects were used as input for
the LDA. The bacteria that were associated with neurolo-
gical symptoms belonged to the Clostridiaceae family (i.e
C. symbosium, C. bolteae, C. spiriforme, C. aldenense, C.
citroniae, C. asparagiforme and E. ramosum) (Fig. 4B).
They were also retained in the LEfSe model in pre-
chemotherapy samples, as an internal validation (not
shown). Most of these taxonomic species that were asso-
ciated with neurological symptoms post-CT were clinically
relevant for the dismal prognosis (as outlined Fig. 1 and
Fig. 2A–D and Supplementary Figs. S2, S3, i.e, C. bolteae,
C. spiroforme, E. ramosum, E.coli, B. uniformis, B. the-
taiotaomicron, Blautia wexlerae, Eggerthella lenta, Ruthe-
nibacterium lactatiformans).
Conversely, some of the bacteria underrepresented in
patients who were less susceptible to develop neurological
side effects also featured in the list of commensals asso-
ciated with good prognosis and/or healthy status (C.aero-
faciens, C.comes, D.piger, R. torques, B. crossotus).
However, it is noteworthy that most of the bacteria asso-
ciated with dismal prognosis that were dominant pre-CT
(and disadvantaged by CT) were especially abundant in the
stools of patients who did not suffer from weight gain (C.
bolteae, C. clostridioforme, C. aldenense, C. hathewayi, E.
ramosum, E. coli, B. uniformis, Eisenbergiella tayi, spp
from the Veillonella genus and Streptococci spp.) (Sup-
plementary Fig. S6, Supplementary Table S4).
The microbiome functional potential was analyzed at the
genetic level in the MG data base of our CANTO cohort
using the HUMAnN3 database [26]. Neurological side
effects were associated with intestinal functional pathways
involving mainly energy production with an enrichment in
the glycolysis pathways, L-histidine degradation, fatty acid
biosynthesis and beta-oxidation, as described for stools
from patients with dismal prognosis. In contrast, microbial
genes coding for enzymes involved in ribonucleotide de
novo biosynthesis, polyamine biosynthesis and the GABA
shunt were linked to neuroprotection (Fig. 4C).
Relevance of the findings in gut humanized avatar
mouse models of BC
In order to show a cause effect relationship between the gut
composition and tumor aggressiveness, we took advantage
of avatar mouse models, which are first conditioned by
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Fig. 4 Metagenomics-based stool composition and gene related
functional pathways are associated with neurological symptoms
diagnosed at 12 months post-chemotherapy (CT). A. Beta-diversity
ordination plot based on principal coordinate analysis of normalized
and standardized data of post-CT fecal microbiota composition in
patients with (yes, blue) and without (no, orange) long-term neurolo-
gical toxicities evaluated 12 months after CT (n= 42). The p value is
indicated at the top of the Y axis. B VIP scores showing the most
discriminant species (only bacteria with prevalence >2.5% were con-
sidered) were obtained within partial least square discriminant analysis
by differentiating between presence (yes, blue) and absence (no,
orange) of neurotoxicity evaluated 12 months after CT (n= 42) in
post-CT stools. C LEfSe method detected differential abundant
metabolic pathways when discriminating between presence (yes, blue
bars) vs absence (no, orange bars) of long-term neurotoxicity in
12 months post-CT samples.
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broad-spectrum antibiotics to eradicate the endogenous
mouse microbiota and then “humanized” by fecal microbial
transplantation (FMT). Such “humanized” immunocompe-
tent C57BL/6 mice were inoculated with syngeneic trans-
plantable AT3 BC cells as previously described [27] to
investigate tumor development in the absence or presence of
chemotherapy (Fig. 5A). We performed oral gavage with
FMT using stools from seven independent HV and five BC
patients at diagnosis (Fig. 5B) for whom the MG analyses
were available (Fig. 5C, D). Fifteen days later, we chal-
lenged recipient avatar mice with a lethal dose of AT3 to
follow BC growth kinetics in comparison with non FMT
“eubiotic” mice reared in specific pathogen-free conditions.
The LEfSe method was used to compare the abundance of
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all bacterial clades according to the clinical status (HV
versus BC). Bacterial taxa with differential abundance
between the two study groups were used as input for the
linear discriminant analysis (LDA) to calculate an effect
size (LEfSe analysis) that revealed a relative dominance of
Alistipes spp. (A. shahii being associated with stage I BC
(Supplementary Fig. S3) and B. longum and C. aerofaciens
in PCoA, in HV compared with BC (Fig. 5C, D), in
accordance with the contrast observed between HV and BC
described in Fig. 2 and S3. When we monitored AT3 tumor
progression, we observed two groups of stools that medi-
ated opposite effects, one group that tended to mitigate
natural tumor progression, called “slow progressors”
(dominated by HV2, HV3, HV7) while the other group
called “fast progressors” that tended to accelerate the natural
kinetics (encompassing BC2, BC4, BC5, HV4-5) (Fig. 5E).
The non-supervised hierarchical clustering of fecal MGS of
the FMT donors could also segregate slow from fast pro-
gressing tumor bearers (Fig. 5F). A closer examination of
the taxonomic species overrepresented in slow (versus fast)
progressors revealed several members of the Eubacterium
genus (E. rectale, E. eligens), A. muciniphila, Actino-
bacteria class (B. longum, C. aerofaciens) and Alispites
shahii, which were already identified in patient stools from
patient with stage I or N- BC pre-or post-CT. In contrast,
fast progressors received fecal material containing MG
species associated with dismal prognosis (such as B. uni-
formis, B. xylanivolvens, B. intestinalis, Fig. 5E).
Next, driven by previous reports showing that ATB
negatively affect the efficacy of CT based on oxaliplatin
[28] or cyclophosphamide (CTX) [7, 8], we addressed the
question as to whether the microbiota composition could
modulate the efficacy of CTX-based therapy in AT3 BC
bearing “humanized” mice (Fig. 6A). “Humanization” by
FMT from four BC patients and five HV (listed in Fig. 5B),
demonstrated that CTX-mediated anticancer effects were
affected by the intestinal microbiota. In the vast majority of
mice bearing a human BC-associated gut microflora, the
tumoricidal activity of CTX was barely significant, con-
trasting with mice that obtained an FMT from HV
(Fig. 6B–D). Taking advantage of the coprophagic behavior
of rodent, we treated mice “humanized” with BC feces and
that were doomed to fail CTX-based chemotherapy by co-
housing with “humanized mice” benefiting from a HV-
derived microbiota or, alternatively, by oral gavage with
HV-derived feces. In 3 independent experiments, HV-
derived microbiota allowed to restore the CTX-mediated
anticancer effects (Fig. 6B–D, Fig. 5B).
Altogether, these experiments demonstrate that the
composition of the fecal microbiota influences the natural
growth of BC (without therapy), as well as the response of
BC to CTX-based CT. Thus, variations in intestinal
microflora is not a mere correlate of BC progression but
rather influence the course of the disease in a causative
fashion.
Discussion
To our knowledge, this study offers the first description of
the gut microbiota repertoire defined by shotgun MG
sequencing of fecal samples in early BC at diagnosis and its
dynamics after adjuvant chemotherapy. The data presented
herein suggest that (i) distinct commensals from the gut
microbiome impact BC prognosis in patients and BC tumor
aggressiveness in mice, (ii) chemotherapy can tilt the bal-
ance between favorable or unfavorable species, and iii)
selected commensals may affect the probability of devel-
oping neurological side effects.
In contrast to previous reports focusing in metastatic
melanoma or advanced NSCLC receiving PD-1-targeting
immune checkpoint blockade (ICB), α diversity was not
predictive of favorable BC prognosis, nor of side effects
[12, 14, 29]. In contrast, β diversity of the gut microbiota
was associated with tumor grading (but not breast cancer
subtype), LN involvement and staging, as well as with
neurological side effects at 12 months. At diagnosis (and
regardless of chemotherapy), fecal composition containing a
relative dominance of the trio of C. bolteae, C. aspar-
agiforme, and B. uniformis was associated with axillary
lymph node invasion, as previously described for resistance
Fig. 5 Gut humanized avatar AT3 tumor bearing mice mirrored
patient prognosis. A Experimental setting of avatar mice. Fecal
microbial transplantation (FMT) of feces from Healthy Volunteers
(HV) or early breast cancer patients (BC) into AT3 tumor bearing
C57BL/6 mice. Arrows details treatments. Each experiment contained
6 mice/groups for each FMT and each donor et was performed at least
two times. B Details on clinical and pathological characteristics of
human donors for FMT (five early BC and seven HV). C Beta-
diversity ordination plot based on principal coordinate analysis of
normalized and standardized data of donors’ fecal microbiota com-
position in BC (orange) and HV (blue) to analyze the most dis-
criminant species in between the two donor groups. D LEfSe (Linear
discriminant analysis of effect size) differentiating BC and HV,
describing the 14 most discriminant species in descending order of
importance in 5 early BC pre-CT versus 7 HV stools used for FMT in
AT3 tumor bearing mice. E AT3 tumor size in each group of FMT at 2
time points, 14 days (Top panel) and 30 days (low panel) after tumor
inoculation. Means are depicted for 5–6 mice/group. The tumor size
changes (%) were compared with special pathogen free conditions (No
FMT) at the same timepoint. A deviation of +20% compared with
special pathogen free conditions (No FMT) was defined as “fast versus
slow” progressors. Each experiment has been performed once for each
donor with 12 FMT performed in a blinded manner. F Heatmap of the
non-supervised hierarchical clustering of microbiota composition of
stool samples across all 12 donors of FMT. Colors (from green to dark
red) shows the row scaled relative abundance of each taxon across all
samples.
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Fig. 6 CTX-mediated tumoricidal activity is affected by the gut
microbiota composition in avatar AT3 bearers. A. Experimental
Setting. As in Fig. 5, FMT using stools from HV or early BC was
performed following 3 days of ATB in specific pathogen-free (SPF)
C57BL/6 mice. Two weeks later, AT3 breast tumors were sub-
cutaneously inoculated. 9 days after, mice were randomly assigned to
cohousing or FMT with different donors (HV or BC) and con-
comitantly treated with 4 intra peritoneal (i.p.) injections of cyclo-
phosphamide (CTX). Tumor size was recorded for each mouse on
days D7, D14, D21 after CTX starting. 5–6 mice/groups for each FMT
and each donor. B–D. Means AT3 tumor sizes ± SEM at different
timepoits (D7, D14, and D21 after CTX starting) showing the BC
induced dysbiosis and compensation with FMT or cohousing with
different HV (described in Fig. 5) resulting in rescued response to
CTX (each color representing one donor, details on donors char-
actheristics are showed on Fig. 5B). Each experiment included 5–6
mice per group. ANOVA statistical analyses of means and SEM: *p <
0.05, **p < 0.01, ***p < 0.001, ns: non-significant.
2788 S. Terrisse et al.
to ICBs in advanced NSCLC and kidney cancers [19, 27].
In contrast, E. rectale, M. smithii, C. comes or C. catus., and
Actinobacteria (C. aerofaciens) that were associated with
the HV status and dominant in feces of N- and/or stage I BC
patients also correlated with favorable prognosis of patients
with kidney cancer or melanoma treated with ICBs [12, 19].
Of note, C. aerofaciens was also retrieved by LEfSe ana-
lysis of the “humanized” gut from AT3 bearing mice
exhibiting slower tumor progression (Fig. 5). Our data are
in line with a pioneering shot gun MG analysis performed
on stools from 18 premenopausal and 44 post-menopausal
women diagnosed with BC [30]. This latter study indicated
significant differences between BC and healthy controls
post-menopause, with increased α diversity and pro-
inflammatory Enterobacteriaceae members (E. coli, Kleb-
siella spp), and a concomitant decrease in Eubacterium
eligens in BC patients (correlating with decreased tumor-
infiltrating lymphocytes, TILs) compared with HVs.
Moreover, HR+ BC, which constitute the largest group
in our study, are not expected to be under strong T cell-
based immunosurveillance. HR+ BC are poorly infiltrated
with TILs. Of note, our work did not reveal any significant
correlation between the gut microbiota and the density of
TILs (not shown). One might speculate that the intestinal
ecosystem of women doomed to develop this BC subtype
might be relatively poor in commensals associated with a
strong immune tonus, such as A. muciniphila, B. fragilis, E.
hirae, Bifidobacteria spp. Eubacteriaceae family members.
Supporting this notion, A. muciniphila was found associated
with small tumor size (pT1) BC in our study. More than
55% women with BC lacked detectable A. muciniphila, in
line with the association of BC with type 2 diabetes and
high BMI, two conditions that are also associated with the
absence of A. muciniphila [31].
Importantly, we found that chemotherapy drastically
shifted the microbiome composition, tilting the balance
towards favorable commensals in a subset of patients.
Hence, in two BC subcohorts, we observed that several
bacterial spp. associated with ATB uptake or resistance to
ICB (i.e Clostridia such as C. hathewayi, C. clos-
tridioforme, C. symbosium, C. aldenense, C. citroniae, E.
ramosum, as well as Veillonella spp, and Eisenbergiella
massiliensis or E. tayi) which were associated with N+
status at diagnosis and neurological side effects, became
less abundant after adjuvant or neoadjuvant treatment with
anthracylines and taxanes. In contrast, CT favored the
colonization or residence of favorable commensals such as
Methanobrevibacter smithii, D. formicigenerans, Blautia
obeum, or R. torques. Importantly, the gut humanized avatar
AT3 bearers that were subjected to FMT containing species
from the Eubacterium genus (E. rectale, E. eligens, E.
ventriosum) or C. aerofaciens exhibited a reduced tumor
growth rate compared with eubiotic control mice. A
pioneering study [32] focusing on the possible involvement
of microbiota changes in the beneficial effects of metro-
nomic (versus standard dosing of) capecitabine in 15
metastatic HER2 negative BC described differences in
commensalism between the two CT regimens and the
association of Slackia and Blautia obeum with poor and
favorable clinical outcome, respectively. Therefore, it will
be important to validate the capacity of specific che-
motherapeutic agents to eliminate unfavorable bacteria or to
expand favorable commensals in future clinical studies.
Very few reports previously evocated a potential impact
of the gut microbiome on BC risk or prognosis [33]. One
study investigated stools from 31 early BC patients by real-
time qPCR of genes encoding for distinct bacterial families
or species-related 16S rRNA [34]. The authors of this study
concluded that Clostridium leptum and C. coccoides clus-
ters, which express β-glucuronidases favoring the reab-
sorption of free estrogen, were enriched in patients with
stage II-III (as opposed to stage I) BC [34]. Our study
supports the previously described deleterious role of Clos-
tridiacae family members (C. citroniae, C. bolteae, C.
clostridioforme, C. symbosium, C. aldenese, C. hathewayi,
C.asparagiforme) across various malignancies (kidney,
lung, and breast cancers) and therapies (ICBs, anthracy-
clines, taxanes, CTX).
Mechanistically, an earlier report pioneered the idea that
microbiota can dictate the prognosis of extraintestinal
ovarian and breast cancers via an effect on Toll-like
receptor 5 (TLR5) [6]. TLR5 recognition of flagellin-
expressing commensals may favor systemic tumor -pro-
moting inflammation and malignant progression of BC.
Thus, TLR5 signaling drives recirculation of IL-6, mobi-
lizes of myeloid suppressor cells and elicits immunosup-
pressive galectin-1-producing γδT cells [6].
More importantly, overt commensal dysbiosis might
cause systemic inflammation that induced collagen deposi-
tion and accelerated fibrosis of the normal and tumor
mammary gland through infiltration of myeloid cells [35].
Besides promoting systemic inflammation, gut dysbiosis
may alter whole body metabolism. Zhu et al. explored
functional features of the gut microbiota in pre- and post-
menopausal control in BC females, and reported that amino
acid transport and nucleotide synthesis dominated the
KEGG modules in pre-menopause, while LPS and beta-
oxidation were mostly found post-menopause [30]. Of note,
our study pointed to the overrepresentation of lipid beta-
oxidation modules in BC patients prone to develop neuro-
logical side effects. Conversely, our study suggested an
association between protection from taxane-induced neu-
rological side effects and the overrepresentation of pur-
inergic pathways in the gut microbiota. These latter finding
might be interpreted to suggest that increased production of
the neuroprotective purine adenosine (which reportedly
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favors neurotransmission [36], affects neuro-immunity [37],
maintains the blood-brain barrier [38] and avoids neurode-
generation [39–41] through effects on A1, A2A, A2B, and
A3 adenosine receptors [42]) might prevent the taxane-
induced neuropathy by direct effects on neural circuitries.
Moreover, the metabolic pathway of polyamines is asso-
ciated with better prognosis and neuroprotection in our
cohort. Polyamines constitute major products of the colonic
microbiota, as shown after oral administration of the
immunogenic commensal A. muciniphila [43]. Polyamines
can improve the intestinal barrier function [44] and cancer
immune-surveillance [45].
Finally, CT stimulate intestinal ketogenesis. Since ketone
bodies favor immunosurveillance [46], this effect may
contribute to the anticancer effects of CT.
Altogether, the findings reported in this study may have
important consequences for the future clinical management
of early BC patients. First, monitoring the presence and
abundance of favorable versus unfavorable commensals
may be important to predict the efficacy of adjuvant or
neoadjuvant chemotherapy. Second, compensatory thera-
pies aimed at providing immunogenic commensals may
turn cold HR+ BC into TIL-enriched tumor microenviron-
ment amenable to ICBs and/or more sensitive to che-
motherapies. Such an effect has been achieved with live
biotherapeutics in preclinical models [9, 27, 47]. Supporting
the notion that metabolism can be kept in check by com-
mensals, a preparation of oral pre-and probiotics (containing
E. halii, A. muciniphila, and inulin) reduced postprandial
glucose levels in type 2 diabetes patients in a randomized
double blind placebo controlled trial [48], confirming earlier
trials [49]. Thus, it is possible to treat human disease by
intervening on the gut microbiota. Third, diet interventions
may represent yet another way to influence the gut micro-
biota. While promising approaches such as fasting or
ketogenic [46] diets have direct cell autonomous or indirect
immune effects on cancer, it remains to be determined
whether fasting-induced microbial shifts may participate in
the immune control of HR+ BC [24]. Thus, future studies
must determine the best strategy to manipulate the intestinal
microbiota to improve the clinical prognosis and quality of
life of BC patients.
Materials and methods
Clinical study
We enrolled patients from CANTO trial (for CANcer
TOxicities NCT01993498), a prospective clinical cohort
including non-metastatic breast cancer (BC). The CANTO
study aims at performing a long-term follow-up of 13 250
women treated for BC over a period of ten years in order to
quantify and prevent chronic toxicities related to treatment
(surgery, radiation therapy, chemo-hormono-therapy). The
present analysis focuses on a first set of 9595 pts enrolled
from 2012 to 2017 with sufficient follow-up and mature
data in 2019, of which 76 were included in the biological
microbiota sub-study (refer to Consort diagram, Supple-
mentary Fig. S1). Patients stools were collected before and
after chemotherapy (adjuvant or neoadjuvant) at home, in
kits including an anaerobic generator (Biomerieux). Sam-
ples were frozen 4–24 h later at −80 °C at Gustave Roussy
Cancer Campus in plastic tubes (Plastic vessel by 1000-
Sarstedt) with or without RNA later. Plasma samples were
collected for 29 BC females: 26 samples before che-
motherapy and 29 after chemotherapy. In parallel, clinical
data were collected prospectively at three time points: at
diagnosis (baseline); 3–6 months after the end of primary
treatment (i.e., primary surgery, chemotherapy, or radio-
therapy, whichever came last), and then 1 year post primary
treatment. Antihuman epidermal growth factor receptor
(HER2) therapy and hormonal therapy could be ongoing, if
indicated. Toxicity data were collected at 3–6 months and 1
year after the end of primary treatment. Clinical character-
istics and toxicities are described in supplemental tables
(Supplementary Tables 1, 2, and 3). CANTO is coordinated
by UNICANCER, the National Cooperative Group of
French Cancer Centers. The study was approved by the
national regulatory authorities and ethics committee (ID-
RCB: 2011-A01095-36, 11-039). All patients enrolled in
the study provided written informed consent, including
consent for the biological data collection.
Furthermore, we used the feces of 54 Italian HV from
Instituto Nazionale dei Tumori center, whose feces were
harvested according to the same procedures and analyzed
together with 282 HV-derived samples selected from
referenced public metagenomes.
Metagenomics analysis
Total fecal DNA was extracted as described [50, 51] and
sequenced using ion-proton technology (ThermoFisher)
resulting in 22.7 ± 0.9 million (mean ± SD) single-end short
reads of 150-base-long single-end reads as a mean. Reads
were cleaned using [52]. Alien Trimmer in order (i) to
remove resilient sequencing adapters and (ii) to trim low
quality nucleotides at the 3′ side using a quality and length
cut-off of 20 and 45 bp, respectively. Cleaned reads were
subsequently filtered from human and other possible food
contaminant DNA (using Human genome RCh37-p10, Bos
Taurus and Arabidopsis thaliana and an identity score
threshold of 97%). MetaPhlAn3 pipelines were used to
profile fastq files deriving from shotgun sequencing in order
to describe the bacterial species present in each sample [53].
These pipelines are based on a gene-reference database,
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thus protein-coding gene markers deriving from the col-
lection of the +100k bacterial genomes (which we espe-
cially focused on) deposited in NCBI or ENA archives.
With few gene markers available for each bacterial species
(ranging from 50 to 400) it was thus possible to ascertain
their presence and relative abundance (expressed in the
interval 0–100%) within assembled shotgun samples. For
the MetaOMineR analyses the gene abundance profiling
was performed using the 9.9 million gene integrated refer-
ence catalog of the human microbiome [54]. Filtered high-
quality reads were mapped with an identity threshold of
95% to the 9.9 million-gene catalog using [55]. Bowtie 2
included in METEOR software [56]. The gene abundance
profiling table was generated by means of a two-step pro-
cedure using METEOR. The gene abundance table was
processed for rarefaction and normalization and further
analysis using the MetaOMineR package [57]. The gene
abundance table was rarefied to 13 million reads per sample
(a threshold chosen to include all samples, but 1 with 12.5
million reads) by random sampling of 13 million mapped
reads without replacement. The resulting rarefied gene
abundance table was normalized according to the FPKM
strategy (normalization by the gene size and the number of
total mapped reads reported in frequency) to give the gene
abundance profile table. Metagenomic species (MGS) are
co-abundant gene groups with more than 500 genes corre-
sponding to microbial species. 1436 MGS were clustered
from 1267 human gut microbiome samples used to con-
struct the 9.9 million-gene catalog [54], as described [58].
Differentially abundant MGS between different patients’
groups were selected using the Wilcoxon test (p < 0.05).
Microbial gene richness (gene count) was calculated by
counting the number of genes that were detected at least
once in a given sample, using the average number of genes
counted in ten independent rarefaction experiments. MGS
richness (MGS count) was calculated directly from the
MGS abundance matrix. For the MetaPhlAn3 analyses fastq
files were cleaned/filtered as described above and under-
went an additional filtering for possible human con-
taminants (reference database GRCh37/hg19) and
contextual quality control using KneadData. This wrapper
entangles Bowtie2 (“-very-sensitive” and “-dovetail” set-
tings) to rule out contaminant sequences and Trimmomatic
(sliding window 20, min-length 50) to exclude low-quality
reads. Filtered reads underwent MetaPhlAn3 pipeline
(default settings) for unambiguous taxonomic classification
and to generate a table of relative abundances for bacterial,
archael, eukaryotic species. Only taxa that were present in at
least 5% of all samples were kept for downstream analysis.
Measurements of α diversity (within sample diversity) in
terms of Shannon index, Simpson index, and richness were
calculated at species level using the diversity function in the
R environment. Exploratory analysis of β-diversity
(between sample diversity) was calculated using the Bray-
Curtis measure of dissimilarity and represented in PCoA.
Supervised PLS-DA and the subsequent VIP were used
to find out the most discriminant bacterial species among
the cohorts, having a prevalence cutoff >=5%. Two-tailed
Mann–Whitney U and Kruskall Wallis tests were employed
using the function in the R environment to assess sig-
nificance for pairwise or multiple comparisons, respec-
tively, considering a P value ≤ 0.05. Longitudinal analysis
differences were assessed by Mann–Whitney U test. All P
values underwent a Benjamini-Hochberg two-stages false
detection rate at 10%. Gene-family and pathway-relative
abundances were generated by HUMAnN3 [53]. Univariate
analyses were performed using LEfSe [59] to estimate the
effect size of features that were statistically significant
among groups. The biomarkers with the highest effect sizes
were reported and discussed. Cross-correlation Pearson
matrices for network analysis (metric=Bray–Curtis,
method = complete linkage) were generated and visualized
with Gephi version 0.9.2.
Metabolomics analysis
Plasma sample preparation
Plasma samples (50 μL) were mixed with 500 µL of the of
ice-cold extraction mixture, allowing protein precipitation
and metabolites extraction, then vortexed and centrifuged
(10 min at 15000 g, 4 °C). Supernatants were collected, split
in 4 fractions, and treated according to the protocols
described in Viltard et al. [60]. Briefly, upper phase of
supernatant was split in three parts: 150 µL were used for
GC-MS experiment in injection vial, 40 µL were used for
the SCFA (Short Chain Fatty Acids) HPLC-MS method,
and 120 µL were used for others UHPLC-MS experi-
mentations. The 4th fraction together with the sample pellet
were re-extracted with an equal volume of 2% SSA (in
meOH), vortexed and centrifuged (10 min at 15000 g, 4 °C)
for polyamines detection.
Widely-targeted analysis of intracellular metabolites
GC/MS. GC-MS/MS method was performed on a 7890B
gas chromatography (Agilent Technologies, Waldbronn,
Germany) coupled to a triple quadrupole 7000C (Agilent
Technologies, Waldbronn, Germany) equipped with a High
sensitivity electronic impact source operating in positive
mode [60].
Targeted analysis of bile acids
Targeted analysis was performed on a RRLC 1260 system
(Agilent Technologies, Waldbronn, Germany) coupled to a
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QTRAP 6500+ (Sciex) equipped with an electrospray
source operating in negative mode. Gas temperature was set
to 450 °C, with ion source gas 1 and 2 set to 30 and 70,
respectively [60].
Targeted analysis of polyamines
Targeted analysis was performed on a RRLC 1260 system
(Agilent Technologies, Waldbronn, Germany) coupled to a
Triple Quadrupole 6410 (Agilent Technologies) equipped
with an electrospray source operating in positive mode. The
gas temperature was set to 350 °C with a gas flow of 12 l/
min. The capillary voltage was set to 3.5 kV [60].
Targeted analysis of short chain fatty acid
Targeted analysis was performed on a RRLC 1260 system
(Agilent Technologies, Waldbronn, Germany) coupled to a
Triple Quadrupole 6410 (Agilent Technologies) equipped
with an electrospray source operating in negative mode. Gas
temperature was set to 350 °C with a gas flow of 12 L/min.
Capillary voltage was set to 4.0 kV [60].
Pseudo-targeted analysis of intracellular metabolites
The profiling experiment was performed with a Dionex
Ultimate 3000 UHPLC system (Thermo Scientific) coupled
to a Q-Exactive (Thermo Scientific) equipped with an
electrospray source operating in both positive and negative
mode and full scan mode from 100 to 1200 m/z. The Q-
Exactive parameters were: sheath gas flow rate 55 a.u.,
auxiliary gas flow rate 15 a.u., spray voltage 3.3 kV, capil-
lary temperature 300 °C, S-Lens RF level 55 V. The mass
spectrometer was calibrated with sodium acetate solution
dedicated to low mass calibration [60].
Statistical analysis
All targeted and pseudo-targeted treated data were merged and
cleaned with a dedicated R (version 3.4) package (@Github/
Kroemerlab/GRMeta). Calculations and statistical tests were
performed using R v3.4. Wilcoxon–Mann–Whitney test was
used to assess differences in concentration between two dif-
ferent groups. Data representation was performed with soft-
wares R v3.6 and Rstudio v1.2.1335 using tidyverse, dplyr,
ggplot2, ggpubr, complexheatmap, and corrplot packages.
Experimental tumor model and treatments
● Mice: All animal experiments were carried out in
compliance with French and European laws and
regulations. The local institutional animal ethics board
and French Ministère de la Recherche approved all
mouse experiments (permission numbers: 2016-049-
4646, 2018-078-17530). Experiments were performed in
accordance with Government and institutional guide-
lines and regulations. Female C57BL/6 were purchased
from Harlan (France). Mice were used between 7 and
12 weeks of age. All mouse experiments were
performed at the animal facility in Gustave Roussy
Cancer Campus where animals were housed in specific
pathogen-free conditions.
● Tumor models and CTX treatment: C57BL/6-derived
AT-3 mouse breast tumor cell line was processed as
previously described [61]. To examine s.c. tumor
growth, mice were inoculated subcutaneously on the
right flank with 5 × 105 of cells and tumor size
monitored. Once tumors were established (20–40
mm2). Mice were injected weekly i.p with 100 mg/kg
of cyclophosphamide (CTX, Endoxan, Baxter provided
by Gustave Roussy) for three injections or equivalent
volume of PBS. Mice were randomized based on their
tumor sizes to homogenize the groups.
Mice were excluded of the analysis if the reached the
endpoint established by ethical committee such as tumor
size or tumor necrosis.
● Antibiotics:Mice were treated with an antibiotic cocktail
(ATB) containing ampicillin (1 mg/ml), streptomycin (5
mg/ml), and colistin (1 mg/ml) (Sigma-Aldrich), in the
drinking water of mice. Antibiotic activity was con-
firmed by cultivating fecal pellets resuspended in BHI
+15% glycerol at 0.1 g/ml on COS (Columbia Agar
with 5% Sheep Blood) plates for 48 h at 37 °C in aerobic
and anaerobic conditions. ATB were given during
3 days and FMT was performed the next day.
● FMT: FMT was performed by thawing fecal material.
Two hundred µL of the suspension was then transferred
by oral gavage into ATB pretreated recipient. In
addition, another 100 µL was applied on the fur of each
animal. Two weeks after FMT, tumor cells were injected
subcutaneously. Mice were treated with CTX or PBS
and randomly assigned to +/− oral gavage of fecal
samples from HV into humanized mice with BC patients
FMT. The experimenter was blinded for the healthy
volunteer or breast cancer status.
● Cohousing experiments: Two weeks after FMT, tumor
cells were injected subcutaneously. Mice were treated
with CTX or PBS, then randomly assigned to +/−
cohousing with humanized mice with HV or BC.
The experimenter was blinded to the healthy or breast
cancer status of the patients. Each experiment included 5-6
mice per group. Data are representative of at least two
independent experiments.
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Statistical analysis
Data analyses and representations were performed either
with the statistical environment, Microsoft Excel or Prism 6
(GraphPad).
The Mann–Whitney U test was used to compare two
independent groups, whereas nonparametric Kruskal–Wallis
tests were implemented for multiple groups. For comparisons
between patient groups, the Mann–Whitney U test P value
was used.
All tests were two-sided and P values < 0.05 were con-
sidered to be statistically significant.
Data from in vivo experiments were expressed as the
mean ± standard error of the mean (SEM). Data are repre-
sentative of at least two independent experiments.
Data availability
Raw data for the metagenomes newly sequenced in this
study are available in NCBI-SRA under the BioProject
PRJNA718520.
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